Bausch + Lomb Co. (NYSE:BLCO) Receives $18.59 Consensus Target Price from Analysts

Bausch + Lomb Co. (NYSE:BLCO) has earned a consensus rating of “Moderate Buy” from the twelve analysts that are presently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $18.59.

BLCO has been the subject of a number of research analyst reports. Evercore ISI upped their price target on Bausch + Lomb from $15.00 to $15.50 and gave the company an “in-line” rating in a report on Tuesday, July 2nd. HC Wainwright lowered their target price on shares of Bausch + Lomb from $20.00 to $19.00 and set a “buy” rating for the company in a report on Monday, August 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $20.00 target price on shares of Bausch + Lomb in a research report on Thursday, August 1st. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Bausch + Lomb from $14.00 to $18.00 and gave the company a “hold” rating in a research report on Thursday, August 1st. Finally, Raymond James assumed coverage on Bausch + Lomb in a report on Wednesday, July 10th. They set an “outperform” rating and a $19.00 price objective on the stock.

Insider Buying and Selling

In related news, CEO Brent L. Saunders purchased 32,250 shares of the business’s stock in a transaction dated Monday, August 5th. The stock was acquired at an average price of $15.66 per share, for a total transaction of $505,035.00. Following the acquisition, the chief executive officer now directly owns 595,169 shares of the company’s stock, valued at approximately $9,320,346.54. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Allianz Asset Management GmbH acquired a new position in shares of Bausch + Lomb during the 4th quarter worth approximately $1,706,000. Quadrature Capital Ltd raised its holdings in shares of Bausch + Lomb by 75.8% in the fourth quarter. Quadrature Capital Ltd now owns 48,258 shares of the company’s stock worth $824,000 after acquiring an additional 20,803 shares during the last quarter. Brandes Investment Partners LP lifted its position in shares of Bausch + Lomb by 11.0% in the fourth quarter. Brandes Investment Partners LP now owns 114,200 shares of the company’s stock valued at $1,948,000 after acquiring an additional 11,321 shares in the last quarter. Freshford Capital Management LLC boosted its stake in shares of Bausch + Lomb by 29.8% during the fourth quarter. Freshford Capital Management LLC now owns 1,754,123 shares of the company’s stock valued at $29,925,000 after acquiring an additional 403,062 shares during the last quarter. Finally, Jump Financial LLC increased its position in Bausch + Lomb by 478.0% during the 4th quarter. Jump Financial LLC now owns 87,100 shares of the company’s stock worth $1,486,000 after purchasing an additional 72,030 shares in the last quarter. Institutional investors and hedge funds own 11.07% of the company’s stock.

Bausch + Lomb Stock Up 0.4 %

Shares of NYSE BLCO opened at $16.31 on Monday. Bausch + Lomb has a 12-month low of $13.16 and a 12-month high of $18.05. The stock has a market cap of $5.74 billion, a P/E ratio of -16.99, a PEG ratio of 1.53 and a beta of 0.47. The company has a current ratio of 1.65, a quick ratio of 1.01 and a debt-to-equity ratio of 0.70. The business’s fifty day simple moving average is $15.93 and its 200-day simple moving average is $15.63.

Bausch + Lomb (NYSE:BLCO) last released its earnings results on Wednesday, July 31st. The company reported $0.13 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.13. Bausch + Lomb had a negative net margin of 10.15% and a positive return on equity of 3.36%. The firm had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same period in the prior year, the firm earned $0.18 earnings per share. The business’s quarterly revenue was up 17.5% compared to the same quarter last year. As a group, equities analysts predict that Bausch + Lomb will post 0.6 EPS for the current fiscal year.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.